EPZM - Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge
- Epizyme continues to advance its confirmatory studies to keep TAZVERIK on the market for treating patients with epithelioid sarcoma and follicular lymphoma.
- Sales of TAZVERIK were low at $6.2 million for Q1 2021, but may be due to the COVID-19 environment which hampered sales. Expanded label should improve sales over time.
- Two basket studies using tazemetostat are expected to be initiated in the second half of 2021; One study will target hematological malignancies and the other study will target solid tumors.
- A label expansion into other populations of patients with follicular lymphoma using TAZVERIK could eventually help improve sales of the drug.
For further details see:
Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge